Tenax Therapeutics LEVEL Setting: The Scientific Rationale for Levosimendan as the First Treatment for PH-HFpEF and the Ongoing Phase 3 LEVEL Study

Click to Watch Replay

April 18, 2024

Source: https://vimeo.com/1023392407?share=copy#t=0

Technology and Heart Failure Therapeutics (THT) 2024

“PH-HFpEF: Levosimendan”

Dr Sanjiv Shah

March 6, 2024

Westin Boston Seaport, Boston

Source: https://tenaxthera.com/wp-content/uploads/2024/03/Shah_Levo_THT-.pdf

Tenax Investor R&D Webinar 2020

Scientific experts will share their perspectives regarding the unmet needs of PH-HFpEF patients and the relevance of the HELP Study results.

Source: https://tenaxthera.com/wp-content/uploads/2022/04/Tenax-Webinar.-Rich-Berkhoff-Bourlag-2020.pdf

Global Cardio Vascular Clinical Trialists Forum 2021

Reducing stressed blood volume with levosimendan

Source: https://tenaxthera.com/wp-content/uploads/2022/04/SRich-presentation-CVCT-2021.pdf

American Heart Association 2021

24-hour Levosimendan Infusion Decreases Biventricular Filling Pressures at Rest and Exercise in PH-HFpEF

Source: https://tenaxthera.com/wp-content/uploads/2022/04/Burkhoff.-AHA-mtg-2021.pdf

American Cardiology Conference 2022

Helping PH-HFpEF Patients Walk Further with Levosimendan

Source: https://tenaxthera.com/wp-content/uploads/2022/04/Borlaug-ACC-2022.pdf

Heart Failure Society of America 2021

Levosimendan Improves Hemodynamics and Submaximal Exercise Capacity in PH-HFpEF: Primary Results from the HELP-PH-HFpEFMulticenter Randomized Controlled Trial

Source: https://tenaxthera.com/wp-content/uploads/2022/04/Bourlag.-Heart-Failure-Society-of-America-2021.pdf